-
-
-
Taiwan’s Gene Therapy Pioneer Dr. Wuh-Liang Hwu Partners with TFBS Bioscience to Advance Gene Therapy for Rare Disease
2025-06-11 Taiwan’s Gene Therapy Pioneer Dr. Wuh-Liang Hwu Partners with TFBS Bioscience to Advance Gene Therapy for Rare Disease Dr. Paul Wuh-Liang Hwu, MD, PhD, Professor Emeritus of Pediatrics and Medical Genetics at National Taiwan University, and Distinguished Research Fellow at the Center for Precision Medicine, China Medical University Hospital, has recently launched a new gene therapy development project targeting Sialidosis, a rare genetic disorder. The research utilizes adeno-associated virus serotype 9 (AAV9) as a vector to deliver the sialidase gene into the human body, offering a potential effective treatment for patients. TFBS Bioscience, serving as the manufacturing partner, will provide a one-stop service for AAV9 vector process development, GMP-grade clinical trial material manufacturing, and quality and safety testing to support Phase I/II clinical trials. Learn more
-
-
-去背.png){kind=logo}
2025-07-16 AAVnerGene and TFBS Bioscience Announce Collaboration to Develop Innovative AAV Vector Technology Platform for Gene Therapy AAVnerGene Inc. and TFBS Bioscience Inc. today announced a collaboration on the development and application of innovative adeno-associated virus (AAV) vector technologies for manufacturing, including key areas such as AAV tropism enhancement and manufacturing process optimization. Learn more 
2025-04-30 TFBS Bioscience is included in the list of “CDMO Companies for Regenerative Medicine Products” Released by METI TFBS Bioscience is included in the list of “CDMO Companies for Regenerative Medicine Products” Released by METI Learn more 
